FILTRAVATE, INC.

LAS CRUCES, NM · Founded 2020 · Biotech · Private

High-performance ultrafiltration membranes for monoclonal antibody and virus filtration in bioprocessing

Claim this profile

Follows are private to you and power your alerts

Updated · filtravate.com

Sector
Biotech
Headquarters
LAS CRUCES, NM
Founded
2020
Latest Form D
$60K, Feb 2022
Total capital
$566K
Federal grants
$256K
1 award · 2022
Rank in peer group#8 of 20
Private capital raised
$310K
2 Form D · last Feb 2022
56 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20212022FEDERAL ↑EQUITY ↓Cumulative $566K$256K1st Form D$250K2nd Form D$60K
20212022FEDERAL ↑EQUITY ↓Cumulative $566K$256K1st Form D$250K2nd Form D$60K

Latest events

  • Federal grantNSF · Phase I · STTR Phase I:Developing antifouling viral clearance membranes to enable efficient monoclonal antibody (mAb) processing$256K
  • Private capital raisedForm D · SEC · 2nd filing$60K
  • Private capital raisedForm D · SEC · 1st filing$250K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 20 peers

Line = median

Biotech · Material

  • Federal grants#8 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Yun Calvin LiResearcherExecutive Officer, DirectorLinked by $256K in grants as PI
  • Robert Calvin GoforthDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .